Assess whether biosimilarity is analytically justified after an FAERS cluster

Situation

Clinical and Evidence Strategy work in a mid-size sponsor after a complete response letter now turns on biosimilarity is analytically justified because an FAERS cluster in a demographic the trials under-enrolled put biosimilar analytical similarity report in play. 505(b)(2) development lead should say what biosimilar analytical similarity report proves.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one an FAERS cluster in a demographic the trials under-enrolled named, so Proceed under protocol follows for this Clinical and Evidence Strategy file.
• The population in biosimilar analytical similarity report is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; Pause the pathway is the honest Pharma & Life Sciences call.
• A mid-size sponsor after a complete response letter already contained an FAERS cluster in a demographic the trials under-enrolled before biosimilar analytical similarity report arrived; no new Clinical and Evidence Strategy path.
• Provenance on biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.